OLMA vs. GHRS, STOK, CALT, ZYME, PHAR, LYEL, ORIC, PHAT, SLN, and CVAC
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include GH Research (GHRS), Stoke Therapeutics (STOK), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Pharming Group (PHAR), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Silence Therapeutics (SLN), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
Olema Pharmaceuticals (NASDAQ:OLMA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
GH Research's return on equity of -14.56% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Olema Pharmaceuticals presently has a consensus target price of $21.67, suggesting a potential upside of 132.23%. GH Research has a consensus target price of $36.67, suggesting a potential upside of 180.76%. Given GH Research's higher probable upside, analysts plainly believe GH Research is more favorable than Olema Pharmaceuticals.
Olema Pharmaceuticals received 4 more outperform votes than GH Research when rated by MarketBeat users. However, 67.86% of users gave GH Research an outperform vote while only 60.53% of users gave Olema Pharmaceuticals an outperform vote.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 23.5% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
GH Research is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Olema Pharmaceuticals had 13 more articles in the media than GH Research. MarketBeat recorded 26 mentions for Olema Pharmaceuticals and 13 mentions for GH Research. Olema Pharmaceuticals' average media sentiment score of 0.64 beat GH Research's score of 0.60 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Summary
Olema Pharmaceuticals beats GH Research on 8 of the 14 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
